Publication in Nature by OMass Founder, Professor Dame Carol Robinson, Shows Power of Native Mass Spectrometry in Drug Discovery by Capturing GPCR Signalling in Native Membrane Environment
Retrieved on:
星期三, 四月 6, 2022
Medicine, Therapy, Lipid, Degenerative disease, National academy, University, Royal, GPCR, Royal Society, University of Oxford, European Chemical Society, Research, Rhodopsin, Louis-Jeantet Prize for Medicine, Kavli Foundation (United States), Drug discovery, Science, Commander (order), Industry, Technology, Membrane protein, Regeneration, Ecosystem, Kavli Institute of Nanoscience, Mass spectrometry, Female, G protein-coupled receptor, Protein, Pharmaceutical industry, Fine chemical, Nature, Chemistry
The paper, for the first time, shows the power of native mass spectrometry in capturing a G protein-coupled receptor (GPCR) signalling cascade in a native membrane environment.
Key Points:
- The paper, for the first time, shows the power of native mass spectrometry in capturing a G protein-coupled receptor (GPCR) signalling cascade in a native membrane environment.
- Native mass spectrometry is a core element of OMass proprietary technology platform, OdyssION, which also integrates novel biochemistry techniques and custom chemistry.
- Professor Robinson has pioneered the field of mass spectrometry and established it as a method to analyse proteins in their native state.
- This latest research proposes a new use of native mass spectrometry through the characterization of GPCR targets utilizing native membrane environments as opposed to purified proteins.